Mineralys Therapeutics, Inc.’s Post

https://lnkd.in/e-Xyeimx   This article perfectly summarizes the scientific importance of the work we’re doing at Mineralys. Along with #hypertension, the #obesity epidemic is driving dysregulated aldosterone production that contributes to #CKD, heart failure and multiple other cardiorenal diseases.   Lorundrostat is our highly selective aldosterone synthase inhibitor, which demonstrated enhanced efficacy in the patients with an elevated BMI. While currently in pivotal trials for uncontrolled and resistant hypertension, it represents a pipeline of broad #cardiorenal disease opportunities in the future.  #businessdevelopment #lifesciencesindustry

Resistant hypertension is defined by high #bloodpressure that persists despite taking ≥3 medications, and among the possible causes is dysregulated aldosterone. Read about this hormone's role, and how we're working to address it. #HighBloodPressureMonth

https://lnkd.in/gWsYUuTZ Article title: Renal denervation- its current status & future prospects for management of Hypertension   Author(s): Sreenivas Kumar Arramraju; Rama Krishna Janapati   Journal: Archives of Clinical Hypertension   Journal ISSN: 2640-771X Introduction: Hypertension is one of the major contributing factor for global burden of cardiovascular morbidity and mortality. It was estimated that 1.13 billion people were affected worldwide and most of them are residing in low and middle income countries [1]. Hypertension was strongly associated with coronary artery disease, cerebrovascular events and peripheral artery disease. The pathogenesis of hypertension is multifactorial and sympathetic nervous system hyperactivity is one of the contributing factor for development and poor control of blood pressure [2]. Oral medications are the mainstay of therapy for hypertension but however around 50% of patients were non adherent to prescribed medication at 1 year follow up [3]. Despite the availability of multiple classes of effective drugs for treatment of Hypertension a large number of patients were not attaining the recommended blood pressure goals. #ArterialBloodPressure #ArterialHypertension #BloodPressureMonitoring #BloodPressureVariability #CardiovascularRisks #CentralBloodPressure #HighBloodPressure #HypertensionDuringPregnancy #HypertensionInChildren #HypertensionInNewborn #HypertensionManagement #HypertensionNeonate #HypertensionNursing #HypertensionNutrition #HypertensionRiskFactors #HypertensionTreatment #Peertechz #PeertechzPublications #HypertensiveCrisis #HypertensiveEmergency #IdiopathicIntracranialHypertension #InducedHypertension #IntracranialHypertension #LowBloodPressure #PersistentPulmonaryHypertension #PortalHypertension #ProtopulmonaryHypertension #PulmonaryHypertension #RenalDisorders #TraumaticIntracranialHypertension

Exciting findings reveal Tirzepatide's future potential. New research shows a significant reduction in Diabetic Peripheral Neuropathy (DPN) risk over 2 years compared to insulin and other therapies, highlighting dual benefits in diabetes and obesity management with potential neuroprotective effects. This suggests broader implications beyond traditional diabetes management. Link: tinyurl.com/5xx9d3fr #DiabetesResearch #Neuroprotection #Tirzepatide"

As I reflect on my career in the healthcare industry, I remember starting out in the anticoagulant space, focusing on atrial fibrillation (AF) and its critical messaging around stroke reduction. Over the years, my journey has led me deeper into cardiac rhythm management, where I've witnessed firsthand just how life-threatening AF can be. One important aspect that often goes overlooked is the devastating strong connection between atrial fibrillation and heart failure. AF can lead to heart failure, and conversely, heart failure can exacerbate AF—it's a vicious cycle that deserves greater attention. AF begets HF, AF begets AF. #AtriCure #AF #SurgicalAblation #Afib

GLP-1 receptor agonists, once used exclusively for diabetes treatment, are emerging as a new category of #weightlossmedications with big potential in #obesitymanagement. Their popularity has significantly risen since 2021 when they were first approved for extended weight management. Raul J. Rosenthal, MD, FASMBS, explains how these latest advancements are transforming obesity care: https://cle.clinic/4exgeuW

I had the pleasure of being interviewed by Diane Macedo from ABC News where we dove deep into a crucial topic: the real power of medications like Semaglutide and other GLP-1 receptor agonists. These aren’t just “weight loss medications.” They are *anti-obesity* treatments with the potential to change millions of lives across America. These medications go beyond shedding pounds—they address obesity as a chronic disease, with far-reaching implications for improving metabolic health, reducing the risk of diabetes, cardiovascular issues, and more. The future of obesity treatment is here, and it’s about so much more than just weight loss. #ObesityMedicine #GLP1 #Semaglutide #MetabolicHealth #DrMau #HealthcareInnovation #Interview #ABCMorningNews #ChronicDiseaseManagement #BetterHealth

🚀 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐎𝐛𝐞𝐬𝐢𝐭𝐲 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭! 🌟 SUN PHARMA's GL0034 (𝐔𝐭𝐫𝐞𝐠𝐥𝐮𝐭𝐢𝐝𝐞) showcased promising results at the 84th Scientific Sessions of the American Diabetes Association in Orlando! 🏥 𝐇𝐞𝐫𝐞'𝐬 𝐰𝐡𝐚𝐭 𝐭𝐡𝐞𝐲 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐞𝐝: 🔹 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥𝐥𝐲 𝐌𝐞𝐚𝐧𝐢𝐧𝐠𝐟𝐮𝐥 𝐖𝐞𝐢𝐠𝐡𝐭 𝐋𝐨𝐬𝐬: Significant reduction in body weight within just 4 weeks. 🔹 𝐌𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐜 𝐈𝐦𝐩𝐫𝐨𝐯𝐞𝐦𝐞𝐧𝐭𝐬: Enhanced glucometabolic parameters and insulin sensitivity. 🔹 𝐋𝐢𝐩𝐢𝐝-𝐋𝐨𝐰𝐞𝐫𝐢𝐧𝐠 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Noticeable decreases in triglycerides and cholesterol levels. 🔹 𝐖𝐞𝐥𝐥-𝐭𝐨𝐥𝐞𝐫𝐚𝐭𝐞𝐝: No treatment-related discontinuations, with mild gastrointestinal side effects. 👥 𝑺𝒕𝒖𝒅𝒚 𝑫𝒆𝒕𝒂𝒊𝒍𝒔: 𝐏𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐧𝐭𝐬: 24 healthy, obese males aged 18-40. 𝐃𝐨𝐬𝐚𝐠𝐞: Weekly doses of GL0034 in varying amounts. This innovative GLP-1 receptor agonist offers a promising future for obesity management and related comorbidities. 🌐 Let's continue to pave the way for better health! 💪 #SunPharma #ObesityTreatment #ClinicalResearch #HealthInnovation

Primary Aldosteronism: an unsuspected culprit of hypertension in lupus? https://lnkd.in/g6kjzHPn https://lnkd.in/gbukWX4y

Body fat is a critical part of human design. The obesity epidemic, the modern miracle of new classes of obesity drug therapy, and more are discussed on this episode. Listen today! https://lnkd.in/g8VW5Hg4